D’Ordine, Alexandra M. http://orcid.org/0000-0003-0553-2615
Jogl, Gerwald http://orcid.org/0000-0002-5465-5315
Sedivy, John M. http://orcid.org/0000-0001-9363-4253
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01 AG016694, P01 AG051449)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM007601)
Article History
Received: 12 July 2023
Accepted: 18 April 2024
First Online: 8 May 2024
Competing interests
: J.M.S. is a cofounder and SAB chair of Transposon Therapeutics, holds equity in PrimeFour and Atropos Therapeutics, and consults for Atropos Therapeutics and Longaevus Technologies. Brown University has filed a pending patent (US20230139684A1) on the inhibitors described in this publication with J.M.S., G.J., and A.M.D. listed as inventors.